The co‐mutation in TET1/2, IDH1/2, DNMT3A, MDS‐related genes, FLT3‐TKD and GATA2 was not found to significantly impact the probability of patients achieving CR/CRi after 1–2 cycles of induction chemotherapy (Figure 3B). This evidence concerns the gene IDH1 and myelodysplastic syndrome.